Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2005 Feb 1;15(3):609-12.

The discovery of a selective, high affinity A(2B) adenosine receptor antagonist for the potential treatment of asthma.

Author information

1
Department of Bioorganic Chemistry, CV Therapeutics, Inc., 3172 Porter Dr., Palo Alto, CA 94304, USA. jeff.zablocki@cvt.com

Abstract

Adenosine has been suggested to play a role in asthma, possibly via activation of A(2B) adenosine receptors on mast cells and other pulmonary cells. We describe our initial efforts to discover a xanthine based selective A(2B) AdoR antagonist that resulted in the discovery of CVT-5440, a high affinity A(2B) AdoR antagonist with good selectivity (A(2B) AdoR K(i)=50 nM, selectivity A(1)>200: A(2A)>200: A(3)>167).

PMID:
15664822
DOI:
10.1016/j.bmcl.2004.11.044
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center